Hengrun Dason and China Resources Double-Crane Announce Exclusive Commercialization Partnership for Relmacabtagene Autoleucel (Hengkailai®)

Dec 17, 2025 18:48 CST Updated 18:48

Hrain Biotechnology

Developer of Tumor Immunotherapy Technology R&D

China Resources Double-Crane

Chemical Pharmaceutical Preparations Manufacturer

December 12, 2025Zhangjiang Pharm Valley Enterprise: Shanghai Hengrun Dasheng Biotechnology Co., Ltd.Announcement on Ranikioleucel Injection (Hengkailai) with China Resources Double-Crane^®) to reach a commercial cooperation, China Resources Double-Crane will obtain Hengkailai^®The exclusive agency rights in China. This medicine isChina's First Fully Self-Developed CD19 CAR-T Product for Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL). This cooperation isA New Exploration of Co-Development Models in China's Tumor Immunotherapy Cell Treatment Field.

(Image source: Hengrun Dasheng)

Lu Wenchao, Chairman and Party Secretary of China Resources Double-Crane, statedShanghai Hengrun Dasheng Biotechnology Co., Ltd. is a company focused on research and innovation in cell therapy within the field of oncology, successfully achieving full-process localization in China for the innovative CAR-T therapy from research and development to production. The field of innovative cancer treatment is one of the strategic layout areas of China Resources Double-Crane Pharmaceutical Co., Ltd. Cooperation that leverages the complementary strengths of state-owned and private enterprises is an important path to promoting innovation and development in the pharmaceutical industry. Taking this cooperation as an opportunity, China Resources Double-Crane will fully utilize its advantages in resource integration and market promotion as a central enterprise, standing shoulder-to-shoulder with Shanghai Hengrun Dasheng to make domestically produced innovative therapies truly serve the health of the Chinese people.

Dr. Fei Huang, Director and General Manager of Shanghai Hengrun Dasheng Biotechnology Co., Ltd., statedAs one of the business units in the healthcare sector under the China Resources Group, China Resources Double-Crane is a large state-owned enterprise with over 80 years of history. It possesses robust commercial channels, extensive terminal coverage, and an international brand advantage, ranking among the top in terms of competitive strength and sustainable development capabilities within China's pharmaceutical industry. This commercial collaboration is believed to fully leverage the strengths of both parties, address more pressing clinical needs, benefit more patients and families, and lay a solid foundation for future comprehensive strategic cooperation.

About Hengkailai^®

In July 2025, the National Medical Products Administration officially approved the Class I innovative biologic product Reniucel Injection (trade name: Hengkailai) submitted by Shanghai Hengrun Dasheng Biotechnology Co., Ltd.^®, English trade name: HICARA^®) New Drug Marketing Application. Heng Kai Lai^®For the treatment of adult relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, diffuse large B-cell lymphoma transformed from follicular lymphoma, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and high-grade B-cell lymphoma not otherwise specified.

Heng Kai Lai^®The entire process of R&D and production is based on Shanghai Hengrun Dasheng Biotechnology Co., Ltd.'s proprietary intellectual property in molecular design, independently constructed process quality system, and a closed, large-scale production platform. This has achieved the full-process localization of CAR-T cell production in China, making it the first approved Chinese-produced CAR-T product utilizing a stable transfected cell line virus process. The achievements of Hengrun Dasheng's proprietary viral vector platform successfully passed the inspection of a high-quality research project by China’s Ministry of Industry and Information Technology in 2023. The platform’s annual production capacity can meet the CAR-T cell preparation needs for more than 10,000 patients.

About Shanghai Hengrun Dasheng Biotechnology Co., Ltd.

Shanghai Hengrun Dasheng Biotechnology Co., Ltd. is an innovative biopharmaceutical company dedicated to the research, development, and production of breakthrough immunotherapy drugs, primarily focusing on the treatment of malignant hematological diseases and solid tumors. With a pioneering focus on the independent research and development of CAR-T products, the company also advances international cutting-edge technologies such as CAR-NK, establishing a product pipeline that spans from early-stage research to mature clinical trial phases. This pipeline demonstrates both diversity and technical foresight. The company has one Class I innovative biologic product already on the market in China and is simultaneously advancing four Class I innovative biologic products (CAR-T cell therapies) through registrational clinical trials.

Source: Shanghai Hengrun Dasheng Biotechnology Co., Ltd.